Monoclonal antibody therapy

Homology Medicines Announces New Approach to Leverage AAVHSC Platform by Delivering One-Time In Vivo Gene Therapy to Produce Antibodies in Humanized Murine Model

Retrieved on: 
Wednesday, April 28, 2021
Branches of biology, Medical specialties, Biology, Immunology, Biotechnology, Gene delivery, Antibody, Glycoproteins, Monoclonal antibody therapy, Humanized antibody, Gene therapy

ET -\nBEDFORD, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today a new approach to its AAVHSC platform that delivers one-time gene therapy to produce antibodies throughout the body.

Key Points: 
  • ET -\nBEDFORD, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today a new approach to its AAVHSC platform that delivers one-time gene therapy to produce antibodies throughout the body.
  • \xe2\x80\x9cThese data demonstrated that our AAVHSCs delivered vectors at a high efficiency to the liver and secrete antibodies throughout the body, which resulted in sustained expression levels consistent with C5 antibody therapeutics in a humanized murine model.
  • Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a particular focus on rare diseases.
  • Homology believes that its compelling preclinical data, scientific expertise, product development strategy, manufacturing capabilities and intellectual property position it as a leader in the development of genetic medicines.

DGAP-News: AFFiRiS AG: Positive preclinical in vivo results with AFFiRiS' antibody mAB C6-17 to treat Huntington's disease to be presented at the 16th Annual Huntington's Disease Therapeutics Conference

Retrieved on: 
Tuesday, April 27, 2021
Medical specialties, Clinical medicine, Medicine, Immunology, Monoclonal antibody, Immunotherapy, Passive immunity, Antibody, Monoclonal antibody therapy, AFFiRiS AG, neurodegenerative diseases, Huntington's disease, AFFIRIS AG, NEURODEGENERATIVE DISEASES, HUNTINGTON'S DISEASE

2020 ).\nAffiris\' poster presentation, "In vivo targeting and reduction of mtHTT protein by passive immunization with the monoclonal antibody C6-17," reports results from a new study with mAB C6-17.

Key Points: 
  • 2020 ).\nAffiris\' poster presentation, "In vivo targeting and reduction of mtHTT protein by passive immunization with the monoclonal antibody C6-17," reports results from a new study with mAB C6-17.
  • "Our previous findings supported mAB C6-17 as a potential passive immunotherapy to treat features of Huntington\'s disease.
  • These new in vivo data are further evidence of the potential of this monoclonal antibody in fighting this disease.
  • "Our findings demonstrate that mAB C6-17 treatment may slow progression of motor deficits by inducing degradation of extracellular mtHTT protein.

ImmunoPrecise Selects LifeSci Advisors as Investor Relations Agent of Record

Retrieved on: 
Wednesday, April 21, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious diseases, Immunology, Branches of biology, Antibody, Epitope, Monoclonal antibody therapy, Biology, Life sciences

b'IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that it has selected and retained LifeSci Advisors as investor relations agent of record.\nJennifer Bath, President and CEO of ImmunoPrecise Antibodies commented, \xe2\x80\x9cWe are pleased to partner with LifeSci Advisors for our investor relations advisory needs during this important stage of our Company\xe2\x80\x99s evolution.

Key Points: 
  • b'IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that it has selected and retained LifeSci Advisors as investor relations agent of record.\nJennifer Bath, President and CEO of ImmunoPrecise Antibodies commented, \xe2\x80\x9cWe are pleased to partner with LifeSci Advisors for our investor relations advisory needs during this important stage of our Company\xe2\x80\x99s evolution.
  • With over 500 clients under contract globally, we look forward to continuing our discovery and development of proprietary novel antibodies while providing CRO services to 70% of the top 20 pharma.\xe2\x80\x9d\nLifeSci Advisors (\xe2\x80\x9cLSA\xe2\x80\x9d), with over 250 employees and a local presence that spans, New York, Chicago, Boston, London, Geneva, Paris, and Tel-Aviv, provides life science companies comprehensive solutions to communications and investor outreach.
  • The Company aims to transform the conventional, multi-vendor, product development model by bringing innovative and high-throughput, data-driven technologies to its partners, incorporating the advantages of diverse antibody repertoires with the Company\xe2\x80\x99s therapeutic antibody discovery suite of technologies, to exploit antibodies of broad epitope coverage, multiple antibody formats, valency and size, and to discover antibodies against multiple/rare epitopes.
  • For further information, visit www.immunoprecise.com or contact [email protected]\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210421005374/en/\n'

Himalaya Therapeutics Announces Appointment of Nicholas Desjardins as Chief Financial Officer

Retrieved on: 
Monday, April 19, 2021
Life sciences, Biotechnology, Health sciences, Biopharmaceutical, Pharmaceutical industry, Pharmacy, BeiGene, Monoclonal antibody therapy

b'SAN DIEGO, April 19, 2021 /PRNewswire/ -- Himalaya Therapeutics ("Himalaya"), a clinical-stage biopharmaceutical company focused on development and commercialization in Greater China of a novel class of investigational antibody therapeutics for the treatment of solid tumor cancer, which are based on the Conditionally Active Biologics ("CAB") technology platform, today announced the appointment of Nicholas Desjardins as chief financial officer and corporate development officer.

Key Points: 
  • b'SAN DIEGO, April 19, 2021 /PRNewswire/ -- Himalaya Therapeutics ("Himalaya"), a clinical-stage biopharmaceutical company focused on development and commercialization in Greater China of a novel class of investigational antibody therapeutics for the treatment of solid tumor cancer, which are based on the Conditionally Active Biologics ("CAB") technology platform, today announced the appointment of Nicholas Desjardins as chief financial officer and corporate development officer.
  • Mr. Desjardins received his M.B.A in Finance from the Yale School of Management, his B.A.
  • Its product candidates have been developed using CAB technology, which is protected by more than 500 issued and pending patents.
  • Himalaya has a co-development and collaboration agreement for an investigational CAB CTLA-4 antibody, BA3071, with BeiGene Ltd. for its development, manufacturing and commercialization in Greater China.\n'

US Cancer Antibody Market, Drug Price, Sales & Clinical Trials Insight to 2026: Insight on FDA Approved 57 Cancer Antibodies Available in the US Market

Retrieved on: 
Friday, April 9, 2021
Life sciences, Medical specialties, Immunology, Clinical medicine, Biotechnology, Antibody, Glycoproteins, Biosimilar, Cancer, Monoclonal antibody therapy, Fresolimumab

DUBLIN, April 9, 2021 /PRNewswire/ -- The "US Cancer Antibody Market, Drug Price, Sales & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 9, 2021 /PRNewswire/ -- The "US Cancer Antibody Market, Drug Price, Sales & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.
  • Cancer antibodies have helped the researchers in leaning the entire cancer therapeutics market towards a great transition i.e.
  • In the US, technology advancement is also considered a democratizing force for boosting the market paradigm for cancer-antibody drug market.
  • US Cancer Antibodies Market Opportunity: > US$ 70 Billion by 2026
    US Cancer Antibodies Market Growth: 100% Absolute Growth Till 2026
    Insight On Clinical Trials by Company, Indication, Patient Segment & Phase
    US Cancer Biosimilar Market Opportunity Insight: > US$ 10 Billion by 2026
    9.

Immutep Announces European Patent Grant For LAG525 Antibody In Combination Therapy

Retrieved on: 
Wednesday, April 7, 2021
Medical specialties, Medicine, Clinical medicine, Immunology, Monoclonal antibodies, Immutep, Biotechnology, Ieramilimab, Novartis, Antibody, Monoclonal antibody therapy, Eftilagimod alpha

The claims of EP3317301 are directed to embodiments of LAG525, a humanised form of Immuteps IMP701 antibody which is out-licensed to Novartis AG.

Key Points: 
  • The claims of EP3317301 are directed to embodiments of LAG525, a humanised form of Immuteps IMP701 antibody which is out-licensed to Novartis AG.
  • In particular, the claims of the patent are directed to compositions comprising LAG525 and spartalizumab, an anti-PD-1 antibody molecule, and related methods of use of the combination in the treatment of cancer.
  • The patent is co-owned by Novartis AG and Immutep S.A.S.
  • IMP701 is a therapeutic antibody originally developed by Immutep S.A. (now Immutep S.A.S.)

US Cancer Biosimilar Market Opportunity Insight: Upwards of US$ 10 Billion by 2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 6, 2021
Pharmaceutical, Health, Oncology, Life sciences, Medical specialties, Immunology, Clinical medicine, Biotechnology, Antibody, Glycoproteins, Biosimilar, Cancer, Fresolimumab, Monoclonal antibody therapy

The "US Cancer Antibody Market, Drug Price, Sales & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Cancer Antibody Market, Drug Price, Sales & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.
  • Cancer antibodies have helped the researchers in leaning the entire cancer therapeutics market towards a great transition i.e.
  • In the US, technology advancement is also considered a democratizing force for boosting the market paradigm for cancer-antibody drug market.
  • US Cancer Antibodies Market Opportunity: > US$ 70 Billion by 2026
    US Cancer Antibodies Market Growth: 100% Absolute Growth Till 2026
    Insight On Clinical Trials by Company, Indication, Patient Segment & Phase
    US Cancer Biosimilar Market Opportunity Insight: > US$ 10 Billion by 2026
    9.

I-Mab and ABL Bio Announce First Patient Dosed in Phase 1 Trial of Bispecific Antibody TJ-L14B/ABL503 in Patients with Advanced or Metastatic Solid Tumors

Retrieved on: 
Tuesday, April 6, 2021
Medical specialties, Clinical medicine, Medicine, Immunology, Clusters of differentiation, Cancer immunotherapy, Monoclonal antibody therapy, Immune system, Antibody, PD-L1, Bispecific monoclonal antibody

Using ABLs Grabody-T bispecific antibody platform technology, TJ-L14B/ABL503 stimulates 4-1BB activation only in the presence of PD-L1 expressing tumor cells to minimize the risk of off-tumor toxicity.

Key Points: 
  • Using ABLs Grabody-T bispecific antibody platform technology, TJ-L14B/ABL503 stimulates 4-1BB activation only in the presence of PD-L1 expressing tumor cells to minimize the risk of off-tumor toxicity.
  • Preclinical studies have demonstrated that the bispecific antibody shows better anti-tumor activity than equimolar doses of single agents alone or in combination.
  • Co-targeting of PD-L1 with a bispecific antibody molecule using this particular platform is postulated to enhance antitumor activity while ensuring the safety of the patients.
  • ABL Bio, Inc. (Kosdaq: 298380) is a South Korean biotechnology company developing antibody therapeutics for immuno-oncology and neurodegenerative diseases.

AbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration

Retrieved on: 
Thursday, April 1, 2021
Health, Other Science, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Immunology, Life sciences, Biotechnology, Biology, AbCellera, Gilead Sciences, Humanized antibody, Monoclonal antibody therapy, Antibody

AbCellera (Nasdaq: ABCL) today announced agreements to expand its collaboration with Gilead Sciences, Inc. (Gilead) including a multi-year, multi-target antibody discovery collaboration and access to AbCelleras humanized mouse technology, the Trianni Mouse.

Key Points: 
  • AbCellera (Nasdaq: ABCL) today announced agreements to expand its collaboration with Gilead Sciences, Inc. (Gilead) including a multi-year, multi-target antibody discovery collaboration and access to AbCelleras humanized mouse technology, the Trianni Mouse.
  • Building on the successful completion of the first collaboration together, under the new agreement AbCellera will generate panels of antibodies for up to eight new targets, across multiple indications, selected by Gilead.
  • We are excited to build on the success of the first program and deepen our relationship with the team at Gilead, said Carl Hansen, Ph.D., CEO and President of AbCellera.
  • AbCelleras partners benefit from an operating system designed to support many antibody modalities, unlock new targets, and increase the speed and the probability of success of their therapeutic antibody discovery programs.

I-Mab and ABL Bio Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid Tumors

Retrieved on: 
Tuesday, March 30, 2021
Clinical medicine, Cancer treatments, Drugs, Orphan drugs, Antineoplastic drugs, Breakthrough therapy, Immunology, Monoclonal antibody therapy, Cancer immunotherapy, PD-1 and PD-L1 inhibitors, Pembrolizumab

The phase 1 clinical trial will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of TJ-CD4B/ABL111 in advanced or metastatic solid tumors.

Key Points: 
  • The phase 1 clinical trial will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of TJ-CD4B/ABL111 in advanced or metastatic solid tumors.
  • "With the FDA approval of the IND application to initiate a phase 1 clinical trial of TJ-CD4B/ABL111, we expect to progress rapidly with the clinical development of TJ-CD4B/ABL111," said Dr.
  • "In partnership with I-Mab, we look forward to providing a superior therapeutic option for patients with advanced and metastatic solid cancers."
  • ABL Bio, Inc. (Kosdaq: 298380) is a South Korean biotechnology company developing antibody therapeutics for immuno-oncology and neurodegenerative diseases.